# GSK3862995B PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gsk3862995b

> The next catalyst for GSK3862995B, sponsored by GSK plc (GSK), is its topline data readout, May to Aug 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GSK3862995B |
| Codes | GSK3862995B |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Bronchiectasis](https://sec-api.dev/indications/bronchiectasis), [Pulmonary Disease, Chronic Obstructive](https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Bronchiectasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07201051 (A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07201051

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Bronchiectasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07201051 (A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07201051

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07915791

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07915791

## Same indication

- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Ohtuvayre (ensifentrine)](https://sec-api.dev/pdufa/ensifentrine) (MRK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340) (SNY)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gsk3862995b.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GSK3862995B PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gsk3862995b

```bibtex
@misc{secapidev_pdufa_gsk3862995b_20261116,
  title        = {GSK3862995B PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gsk3862995b}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gsk3862995b_20261116","title":"GSK3862995B PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gsk3862995b","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
